Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma

Yongshun Chen; Xiaoyuan Wu; Daxuan Hao; Xinyu Cheng; Lei Zhang; Yougai Zhang; Shaobo Ke; Wei Shi; Chunyu He

doi:10.18632/oncotarget.28320

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma

PDF | How to cite

Oncotarget. 2022; 13:1300-1300. https://doi.org/10.18632/oncotarget.28320

Metrics: PDF 622 views | ?

Yongshun Chen^1,2, Xiaoyuan Wu², Daxuan Hao², Xinyu Cheng², Lei Zhang³, Yougai Zhang², Shaobo Ke¹, Wei Shi¹ and Chunyu He²

¹Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China
²Department of Radiation Oncology, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, China
³Department of Nephrology, People’s Hospital of Tibet Autonomous Region, Tibet Autonomous Region, Lhasa, China

Published: December 06, 2022

Copyright: © 2022 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: This observational study was summarized from clinical data, therefore the patients’ informed consents were waived. This study was approved by the Ethics Committee.

Original article: Oncotarget. 2019; 10:4069–4078. DOI: https://doi.org/10.18632/oncotarget.23861

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28320

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma